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Abstract
Aims/hypothesis Delayed-release metformin (Metformin DR)
was developed to maximise gut-based mechanisms of
metformin action by targeting the drug to the ileum.
Metformin DR was evaluated in two studies. Study 1
compared the bioavailability and effects on circulating
glucose and gut hormones (glucagon-like peptide-1, peptide
YY) of Metformin DR dosed twice-daily to twice-daily
immediate-release metformin (Metformin IR). Study 2
compared the bioavailability and glycaemic effects of
Metformin DR dosages of 1,000mg once-daily in the morning,
1,000 mg once-daily in the evening, and 500 mg twice-daily.
Methods Study 1 was a blinded, randomised, crossover study
(three × 5 day treatment periods) of twice-daily 500 mg or
1,000 mg Metformin DR vs twice-daily 1,000 mg Metformin
IR in 24 participants with type 2 diabetes conducted at two
study sites (Celerion Inc.; Tempe, AZ, and Lincoln, NE,
USA). Plasma glucose and gut hormones were assessed over
10.25 h at the start and end of each treatment period; plasma
metforminwasmeasured over 11 h at the end of each treatment
period. Study 2 was a non-blinded, randomised, crossover
study (three × 7 day treatment periods) of 1,000 mg
Metformin DR once-daily in the morning, 1,000 mg
Metformin DR once-daily in the evening, or 500 mg
MetforminDR twice-daily in 26 participants with type 2 diabetes
performed at a single study site (Celerion, Tempe, AZ). Plasma
glucose was assessed over 24 h at the start and end of each
treatment period, and plasma metformin was measured over
30 h at the end of each treatment period. Both studies implement-
ed centrally generated computer-based randomisation using a
1:1:1 allocation ratio.
Results A total of 24 randomised participants were included
in study 1; of these, 19 completed the study and were included
in the evaluable population. In the evaluable population, all
treatments produced similar significant reductions in fasting
glucose (median reduction range, −0.67 to −0.81 mmol/l
across treatments) and postprandial glucose (Day 5 to baseline
AUC0–t ratio=0.9 for all three treatments) and increases in gut
hormones (Day 5 to baseline AUC0–t ratio range: 1.6–1.9 for
GLP-1 and 1.4–1.5 for PYY) despite an almost 60% reduction
in systemic metformin exposure for 500 mg Metformin DR
compared with Metformin IR. A total of 26 randomised
participants were included in study 2: 24 had at least one dose
of study medication and at least one post-dose pharmacokinetic/
pharmacodynamic assessment and were included in the
pharmacokinetic/pharmacodynamic intent-to-treat analysis;
and 12 completed all treatment periods and were included in
the evaluable population. In the evaluable population,
Metformin DR administered once-daily in the morning had
28% (90%CI −16%, −39%) lower bioavailability (least squares
mean ratio of metformin AUC0–24) compared with either once-
daily in the evening or twice-daily, although the glucose-
lowering effects were maintained. In both studies, adverse
events were primarily gastrointestinal in nature, and indicated
similar or improved tolerability for Metformin DR vs
Metformin IR; there were no clinically meaningful differences
in vital signs, physical examinations or laboratory values.
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Conclusions/interpretation Dissociation of gut hormone
release and glucose lowering from plasma metformin expo-
sure provides strong supportive evidence for a distal small
intestine-mediated mechanism of action. Directly targeting
the ileum with Metformin DR once-daily in the morning
may provide maximal metformin efficacy with lower doses
and substantially reduce plasma exposure. Metformin DR
may minimise the risk of lactic acidosis in those at
increased risk from metformin therapy, such as individuals
with renal impairment.
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Abbreviations
AMPK 5′ AMP-activated protein kinase
Cmax Maximum observed plasma concentration
DR Delayed release
DPP-4i Dipeptidyl peptidase-4 inhibitor
FPG Fasting plasma glucose
GLP-1 Glucagon-like peptide-1
IR Immediate release
LS Least squares
MALA Metformin-associated lactic acidosis
OCT Organic cation transporters
PD Pharmacodynamic
PK Pharmacokinetic
PYY Peptide YY
TEAE Treatment-emergent adverse event
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Introduction
The glucose-lowering mechanisms of metformin continue
to be explored and debated despite 50 years of clinical
experience [1]. Until recently, most reports indicated that the
antihyperglycaemic actions of metformin were primarily
attributable to systemic exposure leading to a reduction in liver
gluconeogenesis, with secondary effects including increased
insulin-mediated glucose uptake in peripheral tissue [1, 2].
However, there is increasing evidence that at therapeutic doses
direct or indirect effects in the gastrointestinal tract explain
most, if not all, of metformin’s glucose-lowering actions [3–5].
Reported actions of metformin in the gut include increased
secretion of the enteroendocrine L cell hormones glucagon-
like peptide-1 (GLP-1) and peptide YY (PYY), possibly
through an intestinal 5′AMP-activated protein kinase
(AMPK)-dependent pathway, effects on bile acid metabolism
and effects on the microbiome [3, 4, 6–8]. A gut-mediated
mechanism of action is further supported by the observation
that i.v. metformin has an attenuated glucose-lowering effect
compared with oral metformin in rats [9, 10], and that i.v.
metformin has no acute effects on glucose disposal or hepatic
glucose production in humans [11, 12].
Metformin is primarily absorbed from the duodenum and
jejunum and is not metabolised; the oral bioavailability of
currently available metformin preparations (immediate-
release [IR] and extended release [XR]) is ∼50% [13–16].
Thus, approximately half of a typical metformin dose is
confined to the gut and delivered to the distal small intestine,
where it accumulates in the mucosa at concentrations up to
300 times greater than in plasma [16]. Importantly, even
intravenously administered metformin ultimately accumulates
in the gut [17, 18], presumably as a consequence of active
transport and salivary excretion [15, 17–22]. In mice,
i.v. administered [11C]metformin was shown to accumulate
in the intestinal wall predominantly via organic cation trans-
porters (OCTs) 1 and 2. Intestinal accumulation occurred rap-
idly (<15 min) and to a much greater extent than in the liver,
gall bladder or gastric wall [17]. Because metformin absorption
is limited by the transporter rate [13], lower doses have higher
bioavailability but are disproportionately less effective than
higher doses [23]. This is consistent with the dose–response
characteristics of metformin and its weak pharmacokinetic
(PK)/pharmacodynamic (PD) relationship [24].
We developed a delayed-releasemetformin (Metformin DR)
formulation designed to release at pH 6.5, which is typically
associated with the lower jejunum and ileum, thus bypassing
the major sites of metformin absorption. This formulation has
been shown to result in ∼50% lower plasma exposure com-
pared with identical daily doses of Metformin IR or
Metformin XR [5]. A previous report demonstrated that doses
of 600, 800 and 1,000 mg Metformin DR produced significant
reductions in fasting plasma glucose (FPG) levels over
12 weeks compared with placebo, with a ∼40% increase in
potency compared with Metformin XR [5]. Here, we report
the results of two studies into the effects of Metformin DR
and Metformin IR on gut hormones and both FPG and post-
prandial plasma glucose reductions (study 1), and the effects of
the Metformin DR treatment regimen (once-daily with the
morning or evening meal [once-daily AM or once-daily PM] vs
twice-daily administration) on metformin PK and PD (study 2).
Methods
Metformin DR tablets were produced according to current
goodmanufacturing practices and comprised an IRmetformin
hydrochloride core (Aurobindo Pharma, Hyderabad, India)
overlaid with a proprietary enteric coat. The coat delays
disintegration and dissolution of the tablet until it reaches a
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pH of 6.5 in the distal small intestine. Metformin IR treatment
used tablets with an identical core but without the enteric coat.
Baseline assessments followed identical procedures as those
for active treatment but without study medication administra-
tion. Both study protocols were conducted in accordance with
good clinical practice and approved by the ethics committee of
the participating centres (Celerion Inc., Lincoln, NE, and
Tempe, AZ, USA). All participants provided written informed
consent prior to enrolment. Both studies implemented
centrally generated computer-based randomisation using a
1:1:1 allocation ratio.
Eligible participants for both studies were male or female,
19–70 years of age, with a BMI of 25–40 kg/m2 and type 2
diabetes mellitus treated with diet and exercise or with
metformin and/or a dipeptidyl peptidase-4 inhibitor
(DPP-4i). Thesemedicationswerewithheld for at least 14 days
prior to randomisation. Baseline characteristics are presented
in Table 1.
Study 1: PK/PD evaluation of Metformin DR
Study 1 (Clinicaltrials.gov NCT01677299) was a randomised,
three-period crossover study with 24 participants. Participants
and study site personnel were blinded to treatment
assignment. As the tablet number differed between treatment
groups (two tablets twice-daily for 1,000 mg doses of
Metformin DR and Metformin IR, and one tablet twice-daily
for 500 mg Metformin DR), study medication was
administered by an unblinded site pharmacist or by study site
personnel not involved in study conduct. No other personnel
could see the administered drug and study data were blinded
until the database was locked. Participants received
twice-daily Metformin IR 1,000 mg, Metformin DR
1,000 mg, or Metformin DR 500 mg administered with meals
in separate treatment periods. Five-day treatment periods were
separated by washout intervals of 9–12 days, depending on
participant schedules. At each baseline visit, 16 plasma
samples for PD analysis (by Millipore, St. Charles, MO,
USA) were collected over 10.25 h starting at t =−15 min from
the start of the standardised breakfast at t =0 h (meal details
available in electronic supplementary material [ESM]
Table 1). A standardised lunch was served at t =5 h and study
medication dosing began on the evening of the baseline visit.
For each period, medication was administered every 12 h until
t =−1 min prior to the standardised breakfast on day 5. On day
5, PD samples were obtained at identical time points as those
at baseline, and 13 plasma samples for PK analysis (Celerion,
Lincoln, NE) were collected over an 11 h sampling period
beginning at t =−5 min. Samples for PYY, GLP-1, insulin,
glucose and triacylglycerol measurements were collected in
K2EDTA-containing tubes; and samples for metformin PK
were collected in K3EDTA-containing tubes.
PK and PD variables were estimated using non-
compartmental analysis methods. PK and PD ratios of
variables were derived using the evaluable population (i.e.
randomised participants who completed periods consistent
with protocol procedures). ANOVA was performed on
loge-transformed AUC and maximum plasma concentration
(Cmax) for each treatment compared with Metformin IR (PK)
or baseline (PD). For PK analysis, models included treatment,
sequence and period as fixed effects. For PD analysis, models
included treatment day and sequence as fixed effects. For PK
and PD, participant nested within sequence was included
as a random effect. Loge-transformed results were
back-transformed to the original scale. The 90% CI around
the geometric least squares (LS) mean ratios and p values
are presented.
Study 2: evaluation of the effect of Metformin DR dosing
regimen on metformin PK
Study 2 (Clinicaltrials.gov NCT01804842) was a randomised,
three-period crossover study with 26 participants. Participants
received one of the following non-blinded treatments during
each period: 1,000 mg Metformin DR once-daily AM,
1,000 mg Metformin DR once-daily PM or 500 mg
Metformin DR twice-daily. The study included three 6–
7 day treatment periods (separated by washout periods of 6–
12 days, depending on participant schedules). At each
baseline visit, participants consumed a standardised lunch
(t =−6 h; meal details available in ESM Table 1), dinner
(t= 0 h), snack (t= 3 h), breakfast (t = 12 h) and second lunch
Table 1 Baseline characteristics
Characteristic Study 1 Study 2
n 24 26
Age, years 51.3 ± 10.0 50.9 ± 10.9
Male, % 50 38
Hispanic or Latino, % 58 69
White, black, othera, % 79, 8, 13 92, 8, 0
BMI, kg/m2 33.3 ± 4.1 31.5 ± 3.2
HbA1c, % 7.35± 1.11 7.28± 1.02
HbA1c, mmol/mol 57 56
FPG level, mmol/l 8.94 ± 3.13 9.31± 3.17
Prior metformin use, % 71 73
Washout, days 23 (20–26) 23 (16–36)
Prior DPP-4i use, % 0 8
Washout, days – 22 (16–28)
Data are the mean ± SD or mean (range) for the intent-to-treat population,
which includes all randomised participants who received at least one dose
of study medication; percentages are based on the number of randomised
participants in each study
aOther includes Asian, Pacific Islander/Native Hawaiian or American
Indian/Alaska Native
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(t = 18 h), with 34 plasma samples collected over 24 h starting
immediately prior to dinner (t = −5 min) for analysis of
glucose (Celerion, Tempe, AZ). Once-daily PM and
twice-daily medication began after the final (t = 24 h) glucose
measurement and immediately prior to the second dinner;
once-daily AM medication was initiated with breakfast the
following morning. At the end of each treatment period,
participants performed identical procedures to those
performed at baseline, with the addition of 32 plasma samples
for PK analysis (Celerion, Lincoln, NE) obtained at first lunch
and over the subsequent 30 h period. Urine samples for PK
analysis (PharmaNet Canada, Quebec, QC, Canada) were
collected during this period at 6 h intervals. Glucose, insulin
and PK samples were drawn into sodium fluoride/potassium
oxalate tubes, K2EDTA-containg tubes, and K3EDTA-
containing tubes, respectively.
Plasma PK, urine PK and PD variables were determined
using non-compartmental analysis methods for the PK or PD
intent-to-treat population (randomised participants who
received at least one dose). Ratios of PK variables between
treatments and ratios of PD variables compared with baseline
were derived for participants with complete profiles from at
least two treatment periods. ANOVA was performed on the
loge-transformed AUC and Cmax. For PK, models included
treatment, sequence and period as fixed effects. For PD,
models included pre- vs post-treatment status, sequence and
period as fixed effects. For PK and PD, participant nested
within sequence was included as a random effect.
Loge-transformed results were back-transformed to original
scale. The 90% CI around the geometric LS mean ratios and
p values are presented.
In both studies, safety and tolerability were evaluated
through assessment of adverse events, concomitant
medication use, clinical laboratory values and vital signs. All
treatment-emergent adverse events (TEAEs) were attributed
to the most recent treatment prior to onset.
Results
Study 1: PK/PD evaluation of Metformin DR
All 24 participants received at least one treatment dose of the
study regimen. Demographic and baseline characteristics
(Table 1) were similarly distributed across treatment
sequences. Three participants had adverse events leading to
their withdrawal (one had a serious gastrointestinal stromal
tumour, two had vomiting) and two participants discontinued
early for personal reasons. All 19 participants who completed
the study were considered evaluable (ESM Fig. 1).
Figure 1a presents the mean±SD PK concentrations by
treatment at day 5. After the morning Metformin IR
administration, metformin concentrations rapidly increased
to peak at 1.5 h; in contrast, following administration of both
doses of Metformin DR, concentrations continued to decrease
to 4 h; at 6 h there was a small rise to a level <40% of the peak
level observed withMetformin IR. Plasmametformin concen-
trations for the 1,000 mg Metformin DR dose were higher
than for the 500 mg dose at all time points, but the dose–
response relationship was not linear. Figure 1b,c presents the
relative exposure for twice-daily 500 mg and 1,000 mg
Metformin DR vs twice-daily 1,000mgMetformin IR at steady
state (day 5). Compared with 1,000 mg Metformin IR,
1,000 mg and 500 mg Metformin DR resulted in significantly
lower exposures (AUC, −45% and −57%, respectively). Peak
concentrations were also significantly lower for 1,000 mg
(−35%) or 500 mg (−48%) Metformin DR compared with
1,000 mg Metformin IR.
Figure 2a presents the median and individual participant
changes in FPG from baseline to day 5 by treatment. LS mean
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Fig. 1 Study 1: plasma metformin concentrations and bioavailability. (a)
Steady state plasma metformin concentrations (mean ± SD) by treatment.
White circles, 1,000 mg Metformin IR twice-daily; black squares,
1,000 mg Metformin DR twice-daily; black triangles, 500 mg
Metformin DR twice-daily. All treatments were administered at
t =−1min (arrow) relative to the standardised breakfast (t = 0 h) and lunch
(t = 5 h) (dotted vertical lines). (b, c) Plasma metformin relative bioavail-
ability and exposure at steady state (data are the geometric LS mean and
90% CI for the ratios of twice-daily 1,000 mg Metformin DR [Met DR]
and 500 mg Metformin DR to twice-daily 1,000 mg Metformin IR).
Evaluable population, n= 19. ****p < 0.0001 vs twice-daily 1,000 mg
Metformin IR
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reductions at day 5 were similar among treatment groups and
significantly different from baseline (p < 0.01 for all) as
follows: −1.25 mmol/l for 1,000 mg Metformin IR,
−1.11 mmol/l for 1,000 mg Metformin DR and −0.91 mmol/l
for 500 mg Metformin DR (all twice daily; Table 2). All
treatments significantly decreased plasma glucose AUC at
day 5 by 10% (Fig. 2b–d). There were no significant changes
from baseline in insulin AUC or peak concentrations (data not
shown). Figure 2e–j present the mean plasma GLP-1 and PYY
concentration profiles at baseline and day 5 by treatment and
time point. Baseline plasma GLP-1 and PYY concentrations
were similar among treatments. All metformin treatments
significantly increased gut hormone AUC at day 5 by
62–87% for GLP-1 and by 38–55% for PYY. Although not
pre-specified or powered for between-group comparisons,
there was no significant difference in nominal p values
between each Metformin DR treatment arm and Metformin
IR in the gut hormone response. Fasting plasma GLP-1 and
PYY concentrations also were significantly increased at day 5
for each treatment (Table 2).
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Fig. 2 Study 1: change in plasma
glucose and gut hormone levels.
(a) Individual (median) changes
from baseline to day 5 in FPG
concentrations by treatment.
(b–d) Mean and SEM for plasma
glucose at baseline and day 5.
(e–g) Mean and SEM for plasma
GLP-1 active at baseline and day
5. (h–j) Mean and SEM for PYY
total at baseline and day 5. White
symbols, values at baseline; black
symbols, values at day 5.
Evaluable population, n = 19. All
treatments were administered at
t =−1 min relative to the
standardised breakfast (t = 0 h)
and lunch (t = 5 h; dotted vertical
lines). Met, metformin
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Study 2: effect of Metformin DR dosing regimen
on metformin PK/PD
All 26 participants received at least one dose of studymedication.
Two participants withdrew from the study due to adverse events
(vomiting). Two participants were not included in the PK and PD
intent-to-treat populations because they left the study before the
end of the first treatment period. Twelve randomised participants
completed all treatment periods included in the protocol
procedures and were included in the evaluable population
(ESM Fig. 2). Of those participants excluded from the evaluable
population, six did not complete the study and eight were
non-compliant with the dosing schedule.
Figure 3a presents the mean ± SD plasma metformin
concentrations at steady state by treatment and time point.
Peak plasma concentrations following once-daily PM dosing
were right-shifted compared with those for once-daily AM
dosing, suggesting that the start of metformin absorption
was delayed following an evening dose compared with a
morning dose. Total metformin exposure over 24 h at steady
state was significantly lower (by approximately 30%) for
once-daily AM dosing relative to once-daily PM and twice-
daily dosing (Fig. 3b). The metformin peak concentration
was 33% higher for once-daily PM dosing relative to twice-
daily dosing (Fig. 3c). The mean metformin excretion in urine
over 24 h at steady state was lower for once-daily AM than for
once-daily PM and twice-daily Metformin DR, consistent with
the reduced bioavailability of Metformin DR once-daily AM
(Fig. 3d).
The baseline glucose concentrations were reasonably well
matched between both once-daily dose groups, but the
baseline value for the twice-daily group was modestly lower
(Fig. 4a). Both once-daily dosing regimens resulted in similar,
significant decreases in plasma glucose AUC0–24h of 9% after
meal challenges from baseline, despite a 30% decrease in total
metformin plasma exposure with once-daily AM vs once-daily
PM dosing (Fig. 3b). Twice-daily dosing showed a trend
(p=0.099) for decreased plasma glucose from a baseline of
5%. The mean FPG was decreased at the end of treatment for
all three treatment groups; although no significant differences
were observed among treatments (Fig. 4c), reductions were
greatest following the regimen with the lowest plasma
metformin concentrations (once-daily AM).
Safety and tolerability
Table 3 displays the TEAEs with a >5% incidence in any
treatment arm. Consistent with metformin prescribing
information, TEAEs were primarily gastrointestinal. In
study 1, diarrhoea was reported across all treatment groups,
while nausea (n= 2), vomiting (n=2) and retching (n=1)
occurred only with Metformin IR. Two participants withdrew
because of the TEAE of vomiting withMetformin IR. Of note,
all gastrointestinal events with onset after 500 mg Metformin
DR dosing (diarrhoea, n=2; dyspepsia, n=1; abdominal pain,
n=1) occurred at least 10 days after the last dose of the study
treatment, suggesting that they were unrelated to treatment.
Aside from diarrhoea (reported in Table 3), no additional
gastrointestinal adverse events occurred with 1,000 mg
Metformin DR.
In study 2, the most common adverse events with non-
blinded Metformin DR were gastrointestinal events. Two
participants had the TEAE of vomiting, leading to withdrawal
from the study after twice-daily treatment (one of these events
Table 2 Study 1: change in
pharmacodynamic variables Variable 1,000 mg Met IR
twice-daily (n= 19)
1,000 mg Met DR
twice-daily (n= 19)
500 mg Met DR
twice-daily (n= 19)
FPG, mmol/l
Baseline 11.13± 0.90 10.94 ± 0.93 11.04 ± 0.97
End of treatment 9.88 ± 0.90 9.84± 0.93 10.12 ± 0.97
LS mean difference from baseline −1.25± 0.38 −1.11 ± 0.28 −0.91 ± 0.21
p value 0.0040 0.0009 0.0004
Fasting plasma GLP-1 Active (pmol/l)
Baseline 3.79 ± 1.16 3.93± 1.19 4.73± 1.31
End of treatment 6.32 ± 1.16 5.10± 1.19 6.62± 1.31
LS mean difference from baseline 2.53 ± 0.83 1.17± 0.54 1.89± 0.45
p value 0.0067 0.0444 0.0005
Fasting total plasma PYY (pg/ml)
Baseline 59.30 ± 9.67 57.50 ± 7.92 53.14 ± 10.81
End of treatment 95.05 ± 9.67 75.36 ± 7.92 91.80 ± 10.81
LS mean difference from baseline 35.75 ± 6.30 17.87 ± 6.07 38.66 ± 9.89
p value <0.0001 0.0087 0.0010
Data are the LS mean± SEM for the evaluable population
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occurred 11 days after the last dose of study medication).
There were no clinically meaningful differences in vital signs,
physical examinations or laboratory values.
Discussion
Metformin is the most commonly prescribed oral glucose-
loweringmedication, and is recommended as first-line therapy
by most diabetes professional societies if well tolerated and
not contraindicated because of renal impairment [25]. Despite
decades of research and clinical experience, the primary site
and mechanism of action of metformin is still under debate.
The fact that metformin is not metabolised in vivo and is 50%
bioavailable [13] leads to comparable gut and plasma
exposures with typical dosing, along with substantial
metformin accumulation in the intestine [16]. Nonetheless,
the vast majority of studies have focused on its direct
effects on the liver [26–29], although typically at
suprapharmacological concentrations. In contrast, recent
investigations have explored the gut-mediated actions of
metformin, including effects on gut hormones that regulate
glycaemia and satiety, bile acid secretion, and the gut
microbiome [3, 4, 6–8, 30]. For example, Duca et al showed
that duodenal, but not portal, metformin infusion lowered
blood glucose in insulin-resistant rats through a GLP-1 depen-
dent mechanism [4]. Specifically, they proposed that metfor-
min enhances GLP-1 secretion from intestinal L cells that bind
and activate GLP-1 receptors on the afferent vagus nerve,
leading to reduced hepatic glucose production through a
gut–brain–liver axis. In addition, we recently reported results
from a 12 week clinical study showing an apparent 40%
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Fig. 3 Study 2: change in
metformin concentrations and
bioavailability. (a) Steady state
plasma metformin concentrations
(mean ± SD) by treatment. Inset:
mean plasma metformin
concentration from the time of
dose administration (t = 0). Black
squares, 1,000 mgMetformin DR
once-daily AM; white squares,
1,000 mg Metformin DR once-
daily PM; grey triangles, 500 mg
Metformin DR twice-daily. (b, c)
Plasma metformin (mean and
90% CI) relative bioavailability
and exposure at steady state. (d)
24 h urine excretion (Ae) of
metformin (mean and %CV) by
treatment at steady state.
Evaluable population, n = 12.
Meals were administered at t = 0,
3, 12 and 18 h. **p< 0.01,
*p< 0.05
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increase in potency when metformin is delivered to the ileum
via Metformin DR compared with Metformin XR: half of the
latter is absorbed into the circulation, with the remainder
travelling to the distal small intestine [5].
This report provides data that increases our understanding
of the pharmacology and gut effects of metformin. Our results
demonstrate that the metformin effect of reducing both fasting
and prandial glucose is largely the result of its action on a
target(s) in the lumen of the distal small intestine, rather than
the result of high systemic exposure. Although once-daily and
twice-daily Metformin DR dosing reduced blood glucose to
similar extents, once-daily AM dosing resulted in the lowest
daily metformin exposure. This is consistent with
accumulation in the small intestine, rather than plasma
exposure, being the primary determinant of the glycaemic
response. These findings could also explain why achieving a
maximal glucose-lowering effect with current metformin
requires repeated dosing and why discontinuation of
metformin treatment leads to a gradual, rather than an
immediate, loss of glucose control [31]. This study did not
assess effects on other putative mechanisms of gut-mediated
improvement in glycaemic control with metformin (e.g. bile
acid effect, microbiome effects); therefore, the relative
contributions of gut hormones on glycaemic improvement
for the two treatments cannot be fully discerned.
Nevertheless, the nearly identical improvements in glycaemic
control observed with Metformin IR and Metformin DR
suggest that gut-mediated mechanisms are responsible for
the overwhelming majority of glycaemic improvement
observed at clinically relevant doses.
In study 1, the rate and extent of metformin exposure were
significantly reduced for 1,000 mgMetformin DR twice-daily
compared with 1,000 mg Metformin IR twice-daily. Despite
the differences in metformin exposure, all treatments resulted
in similar, significant reductions in fasting and postprandial
glucose, as well as increases in GLP-1 and PYY from baseline
to day 5. Twice-daily 500 mg Metformin DR was almost as
effective as Metformin IR in reducing plasma glucose and
enhancing gut satiety hormones, suggesting that a total daily
dose of 1,000 mg metformin delivered directly to the ileum
may be close to the maximally effective dose. The observed
increases in GLP-1 are well within the range required to
produce salutary effects on glucose homeostasis [32]. The
reduction in body weight or mitigated weight gain observed
with metformin also may result from alterations in gut
hormones such as PYY [33]. Of note, these hormones may
have additive or synergistic effects on metabolic endpoints
such as glucose control and appetite [34, 35].
In study 2, Metformin DR once-daily dosing regimens
resulted in similar, significant decreases in plasma glucose
after meals compared with baseline (Fig. 4). The mean FPG
was also significantly decreased with all three regimens
compared with baseline, with the numerically greatest
reduction observed with once-daily AM treatment. The slightly
smaller glucose reduction observed with twice-daily treatment
may reflect lower average fasting and postprandial baseline
glucose values for that treatment group (Fig. 4a,b,c). Total
metformin exposure was lower with once-daily AM dosing
than with once-daily PM or twice-daily dosing. Slowed
gastrointestinal transit during sleep [36] following PM dosing
Table 3 TEAEs with a >5% incidence in any treatment arm
TEAE Study 1: double blind Study 2: non-blinded
1,000 mg Met IR
twice-daily
(n= 22)
1,000 mg Met DR
twice-daily
(n= 20)
500 mg Met DR
twice-daily
(n = 20)
1,000 mg Met DR
once-daily AM
(n = 23)
1,000 mg Met DR
once-daily PM
(n= 24)
500 mg Met DR
twice-daily
(n= 23)
Any TEAE 6 (27) 5 (25) 4 (20) 6 (26) 5 (21) 7 (30)
Gastrointestinal disorder 5 (23) 3 (15) 2 (10) 3 (13) 2 (8) 4 (17)
Diarrhoea 3 (14) 3 (15) 2 (10)a 2 (9) 0 (0) 1 (4)
Nausea 2 (9) 0 (0) 0 (0) 0 (0) 0 (0) 2 (9)b
Vomiting 2 (9) 0 (0) 0 (0) 0 (0) 0 (0) 2 (9)b
Nervous system disorder 5 (23) 1 (5) 1 (5) 0 (0) 0 (0) 4 (17)
Dizziness 3 (14) 0 (0) 0 (0) 0 (0) 0 (0) 1 (4)
Headache 2 (9) 1 (5) 1 (5) 0 (0) 0 (0) 1 (4)
General disorder and
administration site conditions
0 (0) 0 (0) 1 (5) 1 (4) 3 (13) 3 (13)
Vessel puncture site pain 0 (0) 0 (0) 0 (0) 1 (4) 0 (0) 2 (9)a
Data are n (%)
a Both events occurred >10 days after the last dose of study medication
bOne of the two events occurred >10 days after last dose of study medication
Met, metformin
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may allow prolonged metformin contact with gut transporters
which modestly increases absorption relative to morning
dosing. Indeed, the right-shifted PK profile with Metformin
DR PM dosing compared with AM dosing (together with
previous findings that Metformin DR PM dosing results in
peak concentrations approximately 10 h post-dose [5]) is
probably responsible for the elevated AM concentrations
observed with Metformin DR vs Metformin IR observed in
study 1.
The adverse event profile observed in study 1 suggests
similar or improved tolerability for Metformin DR vs
Metformin IR, particularly with regard to upper gastrointestinal
tolerability. No nausea or vomiting was reported with either
Metformin DR dose; in contrast, two participants discontinued
because of vomiting withMetformin IR. Diarrhoea appeared to
be dose dependent, with a 14–15% incidence for twice-daily
1,000 mgMetformin IR andMetformin DR, but no events with-
in 10 days of the final dose for twice-daily 500 mg Metformin
DR. Importantly, given the apparent increase in potency of
Metformin DR compared with current metformin formulations,
lower total daily doses are the future clinical target [5].
Metformin DR was also well tolerated in study 2 participants:
only one participant reported nausea/vomiting within 10 days of
treatment. However, as the study was not blinded, no
definitive conclusions can be made based on that data.
Metformin DR may ultimately provide a unique treatment
option for patients with renal impairment owing to its targeted
delivery to the distal small intestine and consequent lower
systemic exposure compared with current metformin.
Specifically, metformin-associated lactic acidosis (MALA) is
a particular concern in patients with impaired renal function
[37]. MALA is a rare [37–39] but life-threatening condition
usually associated with high (>5 μg/ml) systemic metformin
concentrations secondary to overdose or reduced renal
clearance. Even in patients with mild or moderate renal
impairment, a concurrent event that further reduces metformin
clearance and/or alters lactate metabolism (e.g. sepsis, reduced
tissue perfusion, anoxia, impaired hepatic metabolism) may
increase the MALA risk [40]. In these individuals, reducing
metformin exposure by lowering the dose (as is common
practice with drugs that act peripherally and are renally
cleared) leads to both a disproportional increase in
bioavailability and a reduction in ileum exposure [13], which
results in a marked reduction in efficacy [23, 41].
In summary, compared with Metformin IR, delivery of
metformin to the ileum with Metformin DR at the same or
lower doses resulted in comparable glucose lowering and
hormone secretion, but significantly lower systemic exposure
and a similar number or fewer gastrointestinal events. Once-
daily Metformin DR administered in the morning resulted in
the lowest systemic bioavailability while maintaining the
glucose-lowering effect obtained with twice-daily dosing.
These data provide substantial evidence that currently
prescribed metformin predominantly works in the gut. Based
on its gut-restricted properties, Metformin DR could provide a
means of administering metformin to patients for whom it is
currently contraindicated (e.g. those with renal impairment)
and to others who cannot tolerate currently available metformin
formulations.
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